Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.44 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.39 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21140748 | 0.86 | HRH3 (0.45) | HRH3MOGAT2ASIC3KCNH2TMEM97 | |
| SCHEMBL21482067 | 0.84 | HRH3 (0.44) | HRH3MOGAT2ASIC3KCNH2TMEM97 | |
| SCHEMBL28641279 | 0.84 | HRH3 (0.44) | HRH3MOGAT2ASIC3KCNH2TMEM97 | |
| SCHEMBL23032967 | 0.84 | HRH3 (0.44) | HRH3MOGAT2ASIC3KCNH2TMEM97 | |
| SCHEMBL25091108 | 0.83 | MOGAT2 (0.43) | HRH3MOGAT2ASIC3KCNH2TMEM97 | |
| SCHEMBL26418968 | 0.79 | HRH3 (0.49) | HRH3MOGAT2ASIC3KCNH2TMEM97 | |
| SCHEMBL21361596 | 0.79 | CARM1 (0.48) | HRH3ASIC3ACACB | |
| SCHEMBL26167807 | 0.79 | HRH3 (0.40) | HRH3MOGAT2KCNH2TLR7ACACB | |
| SCHEMBL22410358 | 0.79 | HRH3 (0.48) | HRH3MOGAT2ASIC3KCNH2TMEM97 | |
| SCHEMBL21462204 | 0.78 | HRH3 (0.48) | HRH3MOGAT2ASIC3KCNH2TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195524-A1 | PYRIMIDO-PYRIDAZINONE COMPOUND AS TOLL-LIKE RECEPTOR AGONIST | SHANGHAI VISONPHARMA CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| EP-4497752-A1 | PYRIMIDO-PYRIDAZINONE COMPOUND AS TOLL-LIKE RECEPTOR AGONIST | Shanghai Visonpharma Co., Ltd. (CN) | 2025-01-29 | — | — | EP | disclosed |
| WO-2023179567-A1 | PYRIMIDO-PYRIDAZINONE COMPOUND AS TOLL-LIKE RECEPTOR AGONIST | 上海维申医药有限公司 | 2023-09-28 | — | — | WO | disclosed |
| CN-116789671-A | Pyrimidopyridazinones as Toll-like receptor agonists | 上海维申医药有限公司 | 2023-09-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195524-A1 | PYRIMIDO-PYRIDAZINONE COMPOUND AS TOLL-LIKE RECEPTOR AGONIST | TLR8, TLR7, TLR1 | HRH3 966/4885MOGAT2 4258/4885ASIC3 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.